Live updates from AMCP Annual Meeting

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

ensitrelvir - Infectious disease Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision oxylanthanum carbonate (Renazorb) Unicycive Hyperphosphatemia (in...

Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...

Real-world, integrated data follows-up on previous insights, analytics.

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.